TrialNature communications2026

MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.

Alexander T Pearson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.